GMED vs GSK
Globus Medical vs GSK plc — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
GSK
GSK plc
64
Insufficient Data
| Metric | GMED | GSK |
|---|
| AI Score |
71
|
64
|
| Price |
$85.12
|
$50.91
|
| P/E Ratio |
21.45×
|
15.80×
|
| ROE |
11.8%
|
35.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
73.3%
|
| Debt / Equity |
0.02×
|
1.03×
|
| Dividend Yield |
0.0%
|
3.5%
|
| RSI (14) |
75.9
|
39.2
|
| Beta |
0.954
|
0.3
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus GSK.
GMED leads by 7 points.
GMED scores 71/100 (Buy) versus GSK at 64/100 (Insufficient Data).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
GSK Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical